Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) is a rare lung condition characterized by the abnormal growth of neuroendocrine cells in the lungs. It primarily affects ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80 to 85% of all cases of lung cancer. There are different stages of NSCLC, ranging from 0 to 4; ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

A New Ventilator-on-a-Chip Model to Study Lung Damage Sep. 19, 2024 — Scientists are now able to directly compare the different kinds of injury that mechanical ventilation causes to cells in the ...

This important study describes a first-in-human trial of autologous p63+ stem cells in patients with idiopathic pulmonary fibrosis, a lethal condition for which effective treatments are lacking. The ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

Study Links Methylmalonic Acid to Weakening of Immune Cells in Lung Cancer Oct. 31, 2024 — A new study has found a surprising link between high levels of methylmalonic acid and the weakening of ...

The gold standard for finding lung cancer early is computed tomography (CT) lung cancer screening. However, this is limited to people who have smoked. Currently, there are more non-smokers (never ...

WILMINGTON, Del., December 05, 2024--AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.